Cell Culture
Figure 4 Dose response curves of
chemotherapeutic compounds applied to mono- and co- culture spheroids. The
presence of endothelial cells
affected the potency of several of the compounds tested. Assays were performed in triplicate two independent times
including hydrogels, will optimise cell scale-up. Collectively, these complex 3D cell culture models will provide the basis for more predictive and rel- evant drug screening assays and toxicity tests – as well as providing novel systems for basic research – and so aid in the identification of novel disease mechanisms, and reduce the attrition rate in early drug discovery.
DDW
References 1 Xu, X et al. Three- dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol. Adv. 32(7):1256- 1268 (2014). 2 Nyga, A et al. 3D tumour models: novel in vitro approaches to cancer studies. J. Cell Commun. Signal. 5(3):239-248 (2011). 3 Hirschhaeuser, F et al. Multicellular tumor spheroids: An underestimated tool is catching up again. J. Biotechnol. 148(1):3-15 (2010).
Hilary Sherman is an Applications Scientist in the Corning Life Sciences Lab located in Kennebunk, ME. Sherman has been with Corning Incorporated for 12 years and has worked with a wide variety of cell types including mammalian, insect, primary and stem cells in a vast array of applications. Her key roles at Corning involve creating technical doc- uments such as protocols and applications notes as well as providing technical support and training for both the Corning sales force and customers. Sherman received her BS degree in Biology from the University of New Hampshire in 2005.
Dr Richard M. Eglen is Vice-President and General Manager of Corning Life Sciences. Eglen joined Corning in 2011 with more than 35 years’ experi- ence in the Life Science industry. He has authored more than 320 publications, book chapters and patents, and serves on numerous industry, academ- ic advisory and journal editorial boards.
Table 2: The presence of endothelial cells (C166) with tumour cells (HT-29) in a spheroid affected the potency of several chemotherapeutic compounds
46
Audrey Bergeron is an Applications Scientist for Corning Life Sciences (CLS) at the Kennebunk, Maine location. She evaluates new products and develops protocols and technical documents to support CLS products in the areas of Cell Culture, Drug Discovery and Bioprocess. Bergeron received her BA in Biochemistry from Bowdoin College in Brunswick, ME in 2012.
Drug Discovery World Winter 2017/18
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
